CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma.
Gloria Iacoboni, Sascha Dietrich, Nora Liebers
Author Information
- Gloria Iacoboni: Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medicine, Universitat Aut��noma de Barcelona, Bellaterra, Spain. Electronic address: giacoboni@vhio.net.
- Sascha Dietrich: Department of Hematology, University Hospital of D��sseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-D��sseldorf, D��sseldorf, Germany. Electronic address: sascha.dietrich@med.uni-duesseldorf.de.
- Nora Liebers: Department of Hematology, University Hospital of D��sseldorf and Center for Integrated Oncology Aachen-Bonn-Cologne-D��sseldorf, D��sseldorf, Germany.
No abstract text available.
Adult
Humans
Hematopoietic Stem Cell Transplantation
Immunotherapy, Adoptive
Lymphoma, Mantle-Cell
Neoplasm Recurrence, Local
Transplantation, Homologous
